Stifel Maintains Buy on Sabra Health Care REIT, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Manaker maintains a 'Buy' rating on Sabra Health Care REIT (NASDAQ:SBRA) and raises the price target from $14 to $16.
November 07, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel's 'Buy' rating on Sabra Health Care REIT is maintained and the price target is raised to $16.
The 'Buy' rating maintained by Stifel indicates a positive outlook for Sabra Health Care REIT. The increase in price target from $14 to $16 suggests that the analyst sees potential for the stock's price to rise in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100